Management of orbital lymphangioma using intralesional injection of OK-432
- aDepartment of Ophthalmology, Osaka City University Medical School, bDepartment of Ophthalmology, Kashihara City Hospital, cDepartment of Radiology, Osaka City University Medical School
- Dr Yasuhito Suzuki, Department of Ophthalmology, Osaka City University Medical School, Asahi-machi 1-4-3, Abeno-ku, Osaka City, 545-8585, Japanm5253565{at}msic.med.osaka-cu.ac.jp
- Accepted 14 January 2000
Abstract
AIM To treat orbital lymphangioma with an intralesional injection of OK-432 (group AStreptococcus pyogenes of human origin).
METHOD A 14 year old boy had a right orbital cystic lymphangioma. The visual acuity in the eye was 20/28. In an initial treatment, 0.02 mg of OK-432, was injected into the tumour after aspiration of the fluid contents, but no effect was seen. The second treatment was performed with 0.04 mg of OK-432.
RESULT 4 months later, the lesion had totally shrunk to fibrous tissue. The side effects were fever, a local inflammatory reaction lasting 3 days, and increased intraocular pressure, which was managed by draining the fluid contents. Visual acuity improved to 20/15, and the visual field defect and restriction of eye movement seen before treatment disappeared. No recurrence was noted 1 year after treatment.
CONCLUSION An intralesional injection of OK-432 shrunk the lymphangioma without functional disturbance and scar in the facial skin. OK-432 may be useful for orbital lymphangioma, but further studies are still warranted to determine efficacy, complications, and the optimal dose for safe treatment.
